Search Results

Now showing 1 - 6 of 6

Some of the metrics are blocked by your
consent settings
Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population
(2012)
Lilian Jara
;
Patricio Gonzalez-Hormazabal
;
Kerube Cerceño
;
Gabriella A. Di Capua
;
Jose M. Reyes
1Scopus© Citations 36
Some of the metrics are blocked by your
consent settings
90 Role of microrna-145 in epithelial ovarian cancer
(2020)
Carmen Romero
;
Maritza P Garrido
;
Ignacio Torres
;
Andrea Hernandez
;
Jonas Chnaiderman
3
Some of the metrics are blocked by your
consent settings
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
(2021)
Maritza P. Garrido
;
Allison N. Fredes
;
Lorena Lobos-González
;
Manuel Valenzuela-Valderrama
;
Daniela B. Vera
<jats:p>Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal debulking surgery following chemotherapy with platinum/gemcitabine and taxane compounds. During the last years, anti-angiogenic therapy and poly adenosine diphosphate-ribose polymerases (PARP)-inhibitors were introduced in therapeutic schemes. Several studies have shown that these drugs increase the progression-free survival and overall survival of patients with ovarian cancer, but the identification of patients who have the greatest benefits is still under investigation. In the present review, we discuss about the molecular characteristics of the disease, the recent evidence of approved treatments and the new possible complementary approaches, focusing on drug repurposing, non-coding RNAs, and nanomedicine as a new method for drug delivery.</jats:p>
Scopus© Citations 26 2
Some of the metrics are blocked by your
consent settings
NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells
(2020)
Maritza P. Garrido
;
Ignacio Torres
;
Alba Avila
;
Jonás Chnaiderman
;
Manuel Valenzuela-Valderrama
<jats:p>Nerve Growth Factor (NGF) and its high-affinity receptor tropomyosin receptor kinase A (TRKA) increase their expression during the progression of epithelial ovarian cancer (EOC), promoting cell proliferation and angiogenesis through several oncogenic proteins, such as c-MYC and vascular endothelial growth factor (VEGF). The expression of these proteins is controlled by microRNAs (miRs), such as miR-145, whose dysregulation has been related to cancer. The aims of this work were to evaluate in EOC cells whether NGF/TRKA decreases miR-145 levels, and the effect of miR-145 upregulation. The levels of miR-145-5p were assessed by qPCR in ovarian biopsies and ovarian cell lines (human ovarian surface epithelial cells (HOSE), A2780 and SKOV3) stimulated with NGF. Overexpression of miR-145 in ovarian cells was used to evaluate cell proliferation, migration, invasion, c-MYC and VEGF protein levels, as well as tumor formation and metastasis in vivo. In EOC samples, miR-145-5p levels were lower than in epithelial ovarian tumors. Overexpression of miR-145 decreased cell proliferation, migration and invasion of EOC cells, changes that were concomitant with the decrease in c-MYC and VEGF protein levels. We observed decreased tumor formation and suppressed metastasis behavior in mice injected with EOC cells that overexpressed miR-145. As expected, ovarian cell lines stimulated with NGF diminished miR-145-5p transcription and abundance. These results suggest that the tumoral effects of NGF/TRKA depend on the regulation of miR-145-5p levels in EOC cells, and that its upregulation could be used as a possible therapeutic strategy for EOC.</jats:p>
Scopus© Citations 27 3
Some of the metrics are blocked by your
consent settings
Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells
(2022)
Edison Salas-Huenuleo
;
Andrea Hernández
;
Lorena Lobos-González
;
Iva Polakovičová
;
Francisco Morales-Zavala
<jats:p>One of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation.</jats:p>
19Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Association of genetic variants at TOX3, 2q35 and 8q24 with the risk of familial and early-onset breast cancer in a South-American population
(2014)
Isabel Elematore
;
Patricio Gonzalez-Hormazabal
;
Jose M. Reyes
;
Rafael Blanco
;
Teresa Bravo
Scopus© Citations 33 1

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results